Evaluation of Toxicity from High-dose Systemic Administration of Recombinant Adenovirus Vector in Vector-naive and Pre-immunized Mice

Overview

Journal Gene Ther

Date 2005 Jan 14

PMID 15647774

Citations 58

Authors

A N Varnavski

R Calcedo

M Bove

G Gao

J M Wilson

Affiliations

Soon will be listed here.

Abstract

Toxicity associated with in vivo administration of adenovirus (Ad) vectors has been linked to activation of both innate and adaptive immune responses. Pre-existing immunity to the prevalent Ad serotypes, acquired by the majority of the human population as a result of natural infections, has the potential to modulate vector efficacy and safety. Previously, we evaluated some aspects of toxicity from systemic Ad vector in vector-naive and pre-immunized rhesus monkeys. In this report, we summarize data from several studies analyzing toxic effects from systemically administered E1/E3-deleted Ad vector in vector-naive and pre-immunized C57BL/6 mice. Our results indicate that pre-immunization can be associated with increased mortality shortly after systemic administration of Ad. Transient leukopenia and thrombocytopenia were observed early post vector infusion in both vector-naive and pre-immunized animals. Pre-exposure to the vector did not prevent induction of pro-inflammatory cytokines; however, pre-immunized mice showed less tissue toxicity. Growth of bone marrow myeloid and erythroid progenitors was transiently inhibited in pre-immunized animals, but only the myeloid progenitors were affected in vector-naive animals. In summary, pre-existing immunity to Ad vector substantially modifies host immune responses to systemic Ad vector.

Citing Articles

Transient pacing in pigs with complete heart block via myocardial injection of mRNA coding for the T-box transcription factor 18.

Wolfson D, Kim N, Lee K, Beyersdorf J, Langberg J, Fernandez N Nat Biomed Eng. 2024; 8(9):1124-1141.

PMID: 38698155 PMC: 11410671. DOI: 10.1038/s41551-024-01211-9.

Viruses and thrombocytopenia.

Rasizadeh R, Ebrahimi F, Kermanshahi A, Daei Sorkhabi A, Sarkesh A, Nahand J Heliyon. 2024; 10(6):e27844.

PMID: 38524607 PMC: 10957440. DOI: 10.1016/j.heliyon.2024.e27844.

Efficient prime editing in mouse brain, liver and heart with dual AAVs.

Davis J, Banskota S, Levy J, Newby G, Wang X, Anzalone A Nat Biotechnol. 2023; 42(2):253-264.

PMID: 37142705 PMC: 10869272. DOI: 10.1038/s41587-023-01758-z.

Immunogenicity Differences of the ChAdOx1 nCoV-19 Vaccine According to Pre-Existing Adenovirus Immunity.

Kim J, Kim C, Lee J, Lee S, Lee K, Kim J Vaccines (Basel). 2023; 11(4).

PMID: 37112696 PMC: 10145356. DOI: 10.3390/vaccines11040784.

mRNA COVID-19 Vaccines-Facts and Hypotheses on Fragmentation and Encapsulation.

Demongeot J, Fougere C Vaccines (Basel). 2023; 11(1).

PMID: 36679885 PMC: 9864138. DOI: 10.3390/vaccines11010040.

References

Vlachaki M, Hernandez-Garcia A, Ittmann M, Chhikara M, Aguilar L, Zhu X . Impact of preimmunization on adenoviral vector expression and toxicity in a subcutaneous mouse cancer model. Mol Ther. 2002; 6(3):342-8. DOI: 10.1006/mthe.2002.0669. View

Yang Y, Haecker S, Su Q, Wilson J . Immunology of gene therapy with adenoviral vectors in mouse skeletal muscle. Hum Mol Genet. 1996; 5(11):1703-12. DOI: 10.1093/hmg/5.11.1703. View

Lozier J, Metzger M, Donahue R, Morgan R . Adenovirus-mediated expression of human coagulation factor IX in the rhesus macaque is associated with dose-limiting toxicity. Blood. 1999; 94(12):3968-75. View

Varnavski A, Zhang Y, Schnell M, Tazelaar J, Louboutin J, Yu Q . Preexisting immunity to adenovirus in rhesus monkeys fails to prevent vector-induced toxicity. J Virol. 2002; 76(11):5711-9. PMC: 137042. DOI: 10.1128/jvi.76.11.5711-5719.2002. View

Chirmule N, Propert K, Magosin S, Qian Y, Qian R, Wilson J . Immune responses to adenovirus and adeno-associated virus in humans. Gene Ther. 1999; 6(9):1574-83. DOI: 10.1038/sj.gt.3300994. View

Schulick A, Vassalli G, Dunn P, Dong G, Rade J, Zamarron C . Established immunity precludes adenovirus-mediated gene transfer in rat carotid arteries. Potential for immunosuppression and vector engineering to overcome barriers of immunity. J Clin Invest. 1997; 99(2):209-19. PMC: 507788. DOI: 10.1172/JCI119149. View

Schnell M, Zhang Y, Tazelaar J, Gao G, Yu Q, Qian R . Activation of innate immunity in nonhuman primates following intraportal administration of adenoviral vectors. Mol Ther. 2001; 3(5 Pt 1):708-22. DOI: 10.1006/mthe.2001.0330. View

Yang Y, Li Q, Ertl H, Wilson J . Cellular and humoral immune responses to viral antigens create barriers to lung-directed gene therapy with recombinant adenoviruses. J Virol. 1995; 69(4):2004-15. PMC: 188865. DOI: 10.1128/JVI.69.4.2004-2015.1995. View

Nunes F, Furth E, Wilson J, Raper S . Gene transfer into the liver of nonhuman primates with E1-deleted recombinant adenoviral vectors: safety of readministration. Hum Gene Ther. 1999; 10(15):2515-26. DOI: 10.1089/10430349950016852. View

10.

Croyle M, Chirmule N, Zhang Y, Wilson J . "Stealth" adenoviruses blunt cell-mediated and humoral immune responses against the virus and allow for significant gene expression upon readministration in the lung. J Virol. 2001; 75(10):4792-801. PMC: 114234. DOI: 10.1128/JVI.75.10.4792-4801.2001. View

11.

Chen Y, Yu D, Charlton D, Henderson D . Pre-existent adenovirus antibody inhibits systemic toxicity and antitumor activity of CN706 in the nude mouse LNCaP xenograft model: implications and proposals for human therapy. Hum Gene Ther. 2000; 11(11):1553-67. DOI: 10.1089/10430340050083289. View

12.

Zhang Y, Chirmule N, Gao G, Qian R, Croyle M, Joshi B . Acute cytokine response to systemic adenoviral vectors in mice is mediated by dendritic cells and macrophages. Mol Ther. 2001; 3(5 Pt 1):697-707. DOI: 10.1006/mthe.2001.0329. View

13.

Muruve D, Barnes M, Stillman I, Libermann T . Adenoviral gene therapy leads to rapid induction of multiple chemokines and acute neutrophil-dependent hepatic injury in vivo. Hum Gene Ther. 1999; 10(6):965-76. DOI: 10.1089/10430349950018364. View

14.

Otake K, Ennist D, Harrod K, Trapnell B . Nonspecific inflammation inhibits adenovirus-mediated pulmonary gene transfer and expression independent of specific acquired immune responses. Hum Gene Ther. 1998; 9(15):2207-22. DOI: 10.1089/hum.1998.9.15-2207. View

15.

Thomas C, Birkett D, Anozie I, Castro M, Lowenstein P . Acute direct adenoviral vector cytotoxicity and chronic, but not acute, inflammatory responses correlate with decreased vector-mediated transgene expression in the brain. Mol Ther. 2001; 3(1):36-46. DOI: 10.1006/mthe.2000.0224. View

16.

Crystal R . Transfer of genes to humans: early lessons and obstacles to success. Science. 1995; 270(5235):404-10. DOI: 10.1126/science.270.5235.404. View

17.

Worgall S, Wolff G, Crystal R . Innate immune mechanisms dominate elimination of adenoviral vectors following in vivo administration. Hum Gene Ther. 1997; 8(1):37-44. DOI: 10.1089/hum.1997.8.1-37. View

18.

Schmitz H, Wigand R, Heinrich W . Worldwide epidemiology of human adenovirus infections. Am J Epidemiol. 1983; 117(4):455-66. DOI: 10.1093/oxfordjournals.aje.a113563. View

19.

Driesse M, Esandi M, Kros J, Avezaat C, Vecht C, Zurcher C . Intra-CSF administered recombinant adenovirus causes an immune response-mediated toxicity. Gene Ther. 2000; 7(16):1401-9. DOI: 10.1038/sj.gt.3301250. View

20.

Adesanya M, Redman R, Baum B, OConnell B . Immediate inflammatory responses to adenovirus-mediated gene transfer in rat salivary glands. Hum Gene Ther. 1996; 7(9):1085-93. DOI: 10.1089/hum.1996.7.9-1085. View